CUHK Study Proves Ablative Chemoembolization Doubles the Progression-Free Survival for Liver Cancer Patients
From left: Prof. Winnie YEO, from Department of Clinical Oncology; Prof. Simon YU, from Department of Imaging and Interventional Radiology; Dr. Kit Fai LEE, from Department of Surgery, CUHK Medicine
A study conducted by a multidisciplinary team of the Faculty established that “Ablative Chemoembolization” (ACE), a new transarterial treatment, could prolong the progression-free survival of liver cancer patients at the intermediate stage by twice the length of time of “conventional transarterial chemoembolization” (cTACE). Results were published in the medical journal Radiology.